Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07136012) titled 'OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events' on Aug. 18.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Amgen
Condition:
Cardiovascular Disease
Intervention:
Drug: Olpasiran
Recruitment Status: Recruiting
Phase: Phase 3
Date of First Enrollment: September 19, 2025
Target Sample Size: 11000
Countries of Recruitment:
United States
Australia
Canada
Australia
Canada
Uni...